Article
Envision Pharma Group
The Misalignment of Clinical Development and Field Medical Affairs
Summary
In this episode, Tom Caravela is joined by Carrie Caretta and Giancarlo Maranzano from Boehringer Ingelheim to explore the integration of clinical development and field medical affairs. They discuss the strategic role of field medical teams in clinical trial recruitment and how MSLs can effectively contribute to pipeline and asset development. The conversation covers best practices for hiring and training MSLs, evaluating their performance, and the metrics that define success. Carrie and Giancarlo emphasize the importance of collaboration within Medical Affairs and share insights on hiring MSLs early in the process. The episode concludes with reflections and appreciation for the listeners.
My guests today are Carrie Carretta, Executive Director, Clinical Development and Medical Affairs, and Giancarlo Maranzano, Team Leader Field Based Medicine at Boehringer Ingelheim and we discuss the misalignment in clinical development and Field Medical
Carrie and Giancarlo discuss…
👉 The gaps that exist between clinical and field medical
👉 What Pharma companies need to address strategically
👉 How MSLs can be better utilized in clinical development
👉 Ways field medical can be more innovative
👉 How MSLs can assist in the patient recruitment process
clinical development, field medical affairs, MSLs recruitment, pharmaceutical strategies, Boehringer Ingelheim
Related Topics
You May Also Like
Envision Pharma Group
Article
Mateusz T. Wasylewski, Karolina Strzebonska, Magdalena Koperny, Maciej Polak, Jonathan Kimmelman, Marcin Waligora
Clinical development success rates and social value of pediatric Phase 1 trials in oncology
Article
Yassine Kamal Lyauk, Daniël Martijn Jonker, Trine Meldgaard Lund
Dose Finding in the Clinical Development of 60 US Food and Drug Administration-Approved Drugs Compared With Learning vs. Confirming Recommendations
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy